RGMC-selective inhibitors and use thereof
Selective inhibitors of repulsive guidance molecule C (RGMc), are described. Related methods, including methods for making, as well as therapeutic use of these inhibitors in the treatment of disorders, such as anemia, are also provided.
1. An antibody or antigen-binding fragment thereof that binds to Repulsive Guidance Molecule C (RGMc) comprising three heavy chain complementarity determining regions (H-CDRs), H-CDR1, H-CDR2, and H-CDR3, and three light chain CDRs, L-CDR1, L-CDR2, and L-CDR3, wherein:
i) the H-CDR1 comprises the amino sequence of SEQ ID NO: 30, the H-CDR2 comprises the amino sequence of SEQ ID NO: 31, the H-CDR3 comprises the amino sequence of SEQ ID NO: 32, the L-CDR1 comprises the amino sequence of SEQ ID NO: 33, the L-CDR2 comprises the amino sequence of SEQ ID NO: 34, and the L-CDR3 comprises the amino sequence of SEQ ID NO: 35;
ii) the H-CDR1 comprises the amino sequence of SEQ ID NO: 6, the H-CDR2 comprises the amino sequence of SEQ ID NO: 7, the H-CDR3 comprises the amino sequence of SEQ ID NO: 8, the L-CDR1 comprises the amino sequence of SEQ ID NO: 9, the L-CDR2 comprises the amino sequence of SEQ ID NO: 10, and the L-CDR3 comprises the amino sequence of SEQ ID NO: 11;
iii) the H-CDR1 comprises the amino sequence of SEQ ID NO: 14, the H-CDR2 comprises the amino sequence of SEQ ID NO: 15, the H-CDR3 comprises the amino sequence of SEQ ID NO: 16, the L-CDR1 comprises the amino sequence of SEQ ID NO: 17, the L-CDR2 comprises the amino sequence of SEQ ID NO: 18, and the L-CDR3 comprises the amino sequence of SEQ ID NO: 19;
iv) the H-CDR1 comprises the amino sequence of SEQ ID NO: 22, the H-CDR2 comprises the amino sequence of SEQ ID NO: 23, the H-CDR3 comprises the amino sequence of SEQ ID NO: 24, the L-CDR1 comprises the amino sequence of SEQ ID NO: 25, the L-CDR2 comprises the amino sequence of SEQ ID NO: 26, and the L-CDR3 comprises the amino sequence of SEQ ID NO: 27; or
v) the H-CDR1 comprises the amino sequence of SEQ ID NO: 38, the H-CDR2 comprises the amino sequence of SEQ ID NO: 39, the H-CDR3 comprises the amino sequence of SEQ ID NO: 40, the L-CDR1 comprises the amino sequence of SEQ ID NO: 41, the L-CDR2 comprises the amino sequence of SEQ ID NO: 42, and the L-CDR3 comprises the amino sequence of SEQ ID NO: 43; and
wherein the antibody or antigen-binding fragment is an RGMc-selective inhibitor.
2. The antibody or antigen binding fragment of claim 1 , wherein the H-CDR1 comprises the amino sequence of SEQ ID NO: 30, the H-CDR2 comprising the amino sequence of SEQ ID NO: 31, the H-CDR3 comprising the amino sequence of SEQ ID NO: 32, the L-CDR1 comprises the amino sequence of SEQ ID NO: 33, the L-CDR2 comprises the amino sequence of SEQ ID NO: 34, and the L-CDR3 comprises the amino sequence of SEQ ID NO: 35.
3. The antibody or antigen-binding fragment of claim 1 , comprising a heavy chain variable region comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 36 and a light chain variable region comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 37.
4. The antibody or antigen-binding fragment of claim 3 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 36 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 37.
5. The antibody of claim 1 , wherein the antibody is a fully human antibody or a humanized antibody.
6. The antibody of claim 1 , wherein the antibody is a human IgG1 antibody, a human IgG2 antibody, or a human IgG4 antibody.
7. The antibody of claim 6 , wherein the human IgG4 antibody comprises a backbone substitution of Ser to Pro that produces an IgG1-like hinge.
8. The antibody or antigen-binding fragment of claim 1 , wherein the antibody binds an epitope within human RGMc, wherein the epitope comprises at least one of the amino acid residues of YVSSTLSL (SEQ ID NO: 46) and at least one amino acid residue of FHSAVHGIEDL (SEQ ID NO: 47).
9. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment inhibits or reduces RGMc interaction with BMP6.
10. The antibody or antigen-binding fragment of claim 1 , wherein the antibody binds to RGMc to form an antibody-antigen complex, and wherein the antibody induces internalization of the antibody-antigen complex.
11. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment binds to RGMc with a K D value of less than 0.1 nM as determined by Biolayer Interferometry (BLI), surface plasmon resonance (SPR), or solution equilibrium titration-based assay.
12. A pharmaceutical composition comprising the antibody or antigen-binding fragment of claim 1 and a pharmaceutically acceptable carrier.
13. A method for increasing serum iron levels in a subject, the method comprising administering to the subject the pharmaceutical composition of claim 12 in an amount effective to:
i) increase serum iron levels in the subject;
ii) downregulate hepcidin in the subject;
iii) reduce liver hepcidin mRNA levels in the subject;
iv) reduce liver hepcidin protein levels, serum (circulating) hepcidin protein levels, or both in the subject;
v) increase transferrin saturation in the subject;
vi) increase erythropoiesis in the subject;
vii) decrease unsaturated iron binding capacity in the subject;
viii) decrease total iron binding capacity in the subject; and/or,
ix) increase serum ferritin levels in the subject.
14. The method of claim 13 , wherein the subject has received an erythropoietin (EPO/ESA) therapy, a hypoxia-inducible factor (HIF) stabilizer therapy, an intravenous (IV) iron supplementation, or a combination thereof.
15. The method of claim 14 , wherein the subject has manifested or is at risk of an adverse event associated with the EPO therapy, the HIF stabilizer therapy, or the IV iron supplementation.
16. A method of treating an iron disorder in a subject, comprising administering the pharmaceutical composition of claim 12 to the subject in an amount effective to treat the iron disorder in the subject.
17. The method of claim 16 , wherein the iron disorder is anemia.
18. The method of claim 17 , wherein the anemia is iron-refractory iron-deficiency anemia (IRIDA), anemia of chronic disease (ACD), iron deficiency anemia, cancer-related anemia, chemotherapy-related anemia, anemia of critical illness, or microcytic anemia.
19. The method of claim 18 , wherein the anemia of chronic disease (ACD) is associated with chronic bacterial endocarditis, osteomyelitis, rheumatic fever, ulcerative colitis, chronic kidney disease (CKD), or a neoplastic disorder.
20. The method of claim 19 , wherein the ACD is associated with CKD, and wherein the subject is dialysis-dependent.
21. The method of claim 19 , wherein the ACD is associated with CKD, and wherein the subject is non-dialysis-dependent.
22. The method of claim 16 , wherein the iron disorder is a condition involving a functional iron deficiency.
23. The method of claim 16 , wherein the subject has cancer.
24. The method of claim 23 , wherein the cancer is a myeloproliferative disorder.
25. The method of claim 24 , wherein the myeloproliferative disorder is myelofibrosis.
26. The method of claim 23 , wherein the subject has received or is receiving a Janus kinase (JAK) inhibitor.
27. The method of claim 26 , wherein the JAK inhibitor is a JAK1 inhibitor and/or a JAK2 inhibitor.
28. The method of claim 16 , wherein the subject has received or is receiving chemotherapy.
29. The method of claim 16 , wherein the subject has or is at risk of having: fatigue, joint pain, bone or joint disease, rheumatoid arthritis, inflammatory bowel disease, shortness of breath, irregular heartbeat, liver trouble, diabetes, infertility, impotence, depression, mood or mental disorders, poor cognitive skills or neurodegenerative diseases, iron-refractory iron-deficiency anemia, anemia of chronic kidney disease, resistance to erythropoiesis-stimulating agents, aplastic anemia, hypoplastic anemias, paroxysmal nocturnal hemoglobinuria, von Willebrand disease, hemophilia hereditary hemorrhagic telangiectasia, a cardiovascular disease, heart failure, restless leg syndrome, absolute iron deficiency, an inflammatory disease, an infectious disease, a neurological disease, and/or a cardiovascular disease.
30. The method of claim 16 , wherein the pharmaceutical composition is administered in conjunction with an additional therapeutic agent.
31. The method of claim 30 , wherein the additional therapeutic agent is an erythropoietin stimulating agent (ESA), a HIF stabilizer, an iron supplement, and/or a transfusion.
32. The method of claim 31 , wherein the method reduces one or more toxicities associated with the ESA, the HIF stabilizer, the iron supplement, or the transfusion.
33. The method of claim 32 , wherein the toxicities include iron overload and/or a risk of cancer.
34. The method of claim 16 , wherein the amount is an amount effective to achieve a serum ferritin level of 20 nanograms per milliliter of blood.
35. The method of claim 16 , wherein the subject:
a) is currently on an iron therapy and benefits from reducing the dosing of the iron therapy;
b) has previously received an iron therapy and discontinued the iron therapy due to one or more toxicities;
c) has previously received an iron therapy and benefits from reducing dosing of the iron therapy;
d) is at risk of cancer; and/or
e) has been diagnosed with cancer.